Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Unraveling Alzheimer's disease treatments and a look ahead

Unraveling Alzheimer's disease treatments and a look ahead

FromThe Top Line


Unraveling Alzheimer's disease treatments and a look ahead

FromThe Top Line

ratings:
Length:
29 minutes
Released:
Oct 13, 2023
Format:
Podcast episode

Description

In this episode of "The Top Line," Fierce Biotech's Annalee Armstrong engages in a conversation with Howard Fillit, M.D., an expert in the field of Alzheimer's research and the co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation.
They delve into the pioneering work being done in Alzheimer's research, discuss the latest breakthroughs, and explore the ongoing efforts to combat this complex disease.
To learn more about the topics in this episode: 


With full Alzheimer's approval in hand, Eisai and Biogen kick off Leqembi's launch in earnest


Eisai, Biogen's Leqembi may face rollout hurdles now, but experts still like the Alzheimer's drug


Experimental Alzheimer's molecule improves cognition in mice by tamping down on inflammation


Voyager Therapeutics adds anti-amyloid gene therapy to Alzheimer's pipeline


Acumen's stock surges as early Alzheimer's data suggest next-gen Leqembi rival is active

See omnystudio.com/listener for privacy information.
Released:
Oct 13, 2023
Format:
Podcast episode

Titles in the series (99)

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.